Cardiac xenotransplantation faces a 50-day survival ceiling despite genetic modifications to remove immunogenic antigens from porcine hearts. The barrier appears to be 'missing self' rejection—immune responses triggered by the absence of human-specific antigens rather than the presence of foreign ones. Sirolimus, an mTOR pathway inhibitor, could potentially overcome this mechanism while addressing two additional transplant challenges: cardiac hypertrophy and accelerated aging. The longevity implications extend beyond transplantation. Pigs live roughly one-fifth as long as humans, creating an aging mismatch where transplanted organs deteriorate faster than recipient lifespans. Since mTOR suppression promotes healthy aging and extends lifespan across species, sirolimus treatment might synchronize pig organ aging with human longevity timelines. This represents a fascinating convergence where anti-aging mechanisms could solve transplant medicine's most pressing challenge. However, this remains a hypothesis requiring experimental validation. The concept is theoretically sound given mTOR's established roles in immune regulation, cardiac remodeling, and cellular senescence, but translating these mechanisms to successful long-term xenotransplantation will demand rigorous testing in primate models before human applications.